Company Encyclopedia
View More
name
Cocrystal Pharma
COCP.US
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, a HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV.
4.707 T
COCP.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Cocrystal Pharma Receives IRB Approval for Phase 1b Norovirus Study

    Cocrystal Pharma Inc. has received IRB approval from Emory University School of Medicine to start a Phase 1b study for its oral antiviral drug candidate, CDI-988, targeting norovirus infections. This follows FDA clearance of their IND application. Subject enrollment is expected to begin in Q1 2026. The news was originally published by Cocrystal Pharma via GlobeNewswire on December 18, 2025.

    Reuters·
    US
    COCP
    -3.15%
    Reuters·
    US
    COCP
    -3.15%

    Cocrystal Pharma Inc. unveils investor presentation highlighting advances in broad-spectrum antiviral drug development

    Cocrystal Pharma Inc. has released an investor presentation detailing its progress in developing antiviral drugs for influenza, norovirus, and coronaviruses. The company uses a proprietary drug discovery platform based on Nobel Prize-winning technology. Key clinical assets, CDI-988 and CC-42344, have shown positive Phase 1 results. The company is also pursuing government contracts for pandemic preparedness and operates cost-efficiently with no debt. The full presentation is available online.

    Reuters·
    US
    COCP
    -3.15%
    Reuters·
    US
    COCP
    -3.15%

    Dir Frost Buys 20,000 ($18.8K) Of Cocrystal Pharma Inc [COCP]

    Frost Phillip Director and Beneficial Owner of Cocrystal Pharma Inc [COCP] filed a Form 4 on November 25, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date11/25/25TransactionPurchaseShares20,000Price$0.94Value$18,812Ending Holdings: 1,726,651 (27,100 - Direct, 1,699,551 - Indirect) For a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    COCP
    -3.15%
    Reuters·
    US
    COCP
    -3.15%

    Cocrystal Pharma Director and 10% Owner Phillip Frost Reports Acquisition of Common Shares

    Phillip Frost, a Director and 10% Owner of Cocrystal Pharma Inc., reported the acquisition of common shares of the company. The original filing was published via EDGAR by the U.S. Securities and Exchange Commission on November 25, 2025.

    Reuters·
    US
    COCP
    -3.15%
    Reuters·
    US
    COCP
    -3.15%

    Cocrystal Pharma | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    COCP
    -3.15%
    LB filings·
    US
    COCP
    -3.15%
    © 2025 Longbridge｜Disclaimer